Swiss Paraplegic Research, Nottwil
Quick facts
Marketed products
- Polyhexanide · Other
- Rivaroxaban Oral Tablet · Cardiovascular
Rivaroxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation. - Uro-Vaxom
Phase 2 pipeline
- antimuscarinic treatment
- Injection of Onabotulinum toxin · Neurology
Blocks acetylcholine release at neuromuscular junctions - opiate with bolus
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: